ORIC Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to Oric Pharmaceuticals, Inc.'s net margin of 20.83%. Oric Pharmaceuticals, Inc.'s return on equity of -41.02% beat Johnson & Johnson's return on equity of 34.46%.

Oric Pharmaceuticals, Inc. has a consensus price target of $21.23, signalling upside risk potential of 57.85%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -6.41%. Given that Oric Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Oric Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Oric Pharmaceuticals, Inc. has a beta of 1.280, which suggesting that the stock is 27.972% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Oric Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.09% to investors and pays a quarterly dividend of $1.30 per share. Oric Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oric Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Oric Pharmaceuticals, Inc.'s net income of -$30.5M is lower than Johnson & Johnson's net income of $5.1B. Notably, Oric Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oric Pharmaceuticals, Inc. is -- versus 6.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -- compared to Oric Pharmaceuticals, Inc.'s net margin of 47.99%. Oric Pharmaceuticals, Inc.'s return on equity of -41.02% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Oric Pharmaceuticals, Inc. has a consensus price target of $21.23, signalling upside risk potential of 57.85%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.64%. Given that Oric Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Oric Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Oric Pharmaceuticals, Inc. has a beta of 1.280, which suggesting that the stock is 27.972% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.361%.

Oric Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oric Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Oric Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. Oric Pharmaceuticals, Inc.'s net income of -$30.5M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Oric Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 40.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oric Pharmaceuticals, Inc. is -- versus 21.20x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Oric Pharmaceuticals, Inc.'s net margin of --. Oric Pharmaceuticals, Inc.'s return on equity of -41.02% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Oric Pharmaceuticals, Inc. has a consensus price target of $21.23, signalling upside risk potential of 57.85%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.09 which suggests that it could grow by 90.46%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Oric Pharmaceuticals, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Oric Pharmaceuticals, Inc..

Oric Pharmaceuticals, Inc. has a beta of 1.280, which suggesting that the stock is 27.972% more volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.926, suggesting its more volatile than the S&P 500 by 92.554%.

Oric Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oric Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Oric Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Oric Pharmaceuticals, Inc.'s net income of -$30.5M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Oric Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oric Pharmaceuticals, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Oric Pharmaceuticals, Inc.'s net margin of -9.34%. Oric Pharmaceuticals, Inc.'s return on equity of -41.02% beat Pfizer Inc.'s return on equity of 8.69%.

Oric Pharmaceuticals, Inc. has a consensus price target of $21.23, signalling upside risk potential of 57.85%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 2.81%. Given that Oric Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Oric Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Oric Pharmaceuticals, Inc. has a beta of 1.280, which suggesting that the stock is 27.972% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.65%.

Oric Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.22% to investors and pays a quarterly dividend of $0.43 per share. Oric Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Oric Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Oric Pharmaceuticals, Inc.'s net income of -$30.5M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Oric Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oric Pharmaceuticals, Inc. is -- versus 2.52x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.